The tumour-infiltrating lymphocyte therapy, or TIL therapy, is marketed as lifileucel and uses a patient’s own cells to train their immune system to find and attack cancer.
The tumour-infiltrating lymphocyte therapy, or TIL therapy, is marketed as lifileucel and uses a patient’s own cells to train their immune system to find and attack cancer.
If you’re not enjoying these emails, please tell us how we can make them better by emailing storyalertfeedback@thestar.ca. Or, if you’d prefer, you can unsubscribe from this newsletter by clicking the first link below.
